Oxford Genetics, a provider of synthetic biology-based technologies for biologics discovery, development and delivery, has established a new agreement with clinical-stage gene therapy company, MeiraGTx. The collaboration will enable Oxford Genetics and MeiraGTx to develop novel adeno-associated virus (AAV) vectors, as well as packaging and producer cell lines. The companies aim to create a fully scalable AAV production system that can satisfy the requirements for increased viral vector yields...